EP Patent

EP4025191A1 — Pharmaceutical compositions of abiraterone acetate

Assigned to Zentiva KS · Expires 2022-07-13 · 4y expired

What this patent protects

The invention provides immediate release pharmaceutical compositions comprising amorphous or predominantly amorphous abiraterone acetate or a salt of abiraterone acetate with a higher solubility and bioavailability, compared to the original dosage form comprising crystalline abir…

USPTO Abstract

The invention provides immediate release pharmaceutical compositions comprising amorphous or predominantly amorphous abiraterone acetate or a salt of abiraterone acetate with a higher solubility and bioavailability, compared to the original dosage form comprising crystalline abiraterone acetate. Improvement in solubility was demonstrated in an in-vitro experiment and in-vivo improvement in bioavailability was demonstrated in rat models and human volunteers.

Drugs covered by this patent

Patent Metadata

Patent number
EP4025191A1
Jurisdiction
EP
Classification
—
Expires
2022-07-13
Drug substance claim
No
Drug product claim
No
Assignee
Zentiva KS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.